Intravitreal anti‐vascular endothelial growth factor injections and risks of stroke in patients with neovascular age‐related macular degeneration—A registry‐based cohort study
Even though the risk is small, intravitreal injections with anti-VEGF agents for the treatment of nAMD are associated with an increased risk of stroke/TIA. The risk seems to be higher within 60 days of last injection. An assessment of high-risk populations and risk-benefit weighting is necessary before intravitreal anti-VEGF injections are considered.
Authors
- Inger Westborg (ORCID: https://orcid.org/0000-0002-2147-602X)
- Mia von Euler (ORCID: https://orcid.org/0000-0002-3845-8100)
- Fredrik Jönsson (ORCID: https://orcid.org/0000-0002-5259-4731)
- Karin Söderberg (ORCID: https://orcid.org/0000-0002-3494-9535)
- Alaa Hisham Falemban (ORCID: https://orcid.org/0000-0002-1335-1788)
- S. Almlöf‐Sarman
Institutions
- Karolinska University Hospital (SE)
- Umm al-Qura University (SA)
- Örebro University (SE)
- Karolinska Institutet (SE)
- S:t Eriks Ögonsjukhus (SE)
- Umeå University (SE)
Publication Details
- Journal
- Acta Ophthalmologica
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1111/aos.17534
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71